Sun Pharma Q3 Results FY2023, PAT at Rs. 21660 million

Before investing in securities, consider your investment objective, level of experience and risk appetite carefully. Kindly note that, this article does not constitute an offer or solicitation for the purchase or sale of any financial instrument.

These articles have been prepared by 5paisa and is not for any type of circulation. Any reproduction, review, retransmission, or any other use is prohibited. 5paisa shall not be responsible for any unauthorized circulation, reproduction or distribution of this material or contents thereof to any unintended recipient. Kindly note that this page of blog/articles does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. This article is prepared for assistance only and is not intended to be and must not alone be taken as the basis of an investment decision. The value of the investments may be affected generally by factors affecting financial markets, such as price and volume, volatility in interest rates, currency exchange rates, changes in regulatory and administrative policies of the Government or any other appropriate authority (including tax laws), or other political and economic developments. Please note that past performance of financial products and instruments does not necessarily indicate the prospects and performance thereof. The investors are not being offered any guaranteed or assured returns.

The securities quoted in the article are exemplary and are not recommendatory. The investors should make such investigations as it deems necessary to arrive at an independent evaluation of use of the trading platforms mentioned herein. The trading avenues discussed, or views expressed may not be suitable for all investors. 5paisa will not be responsible for the investment decisions taken by the clients.